

Original Investigation

Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population

Harinder S. Chahal, PharmD, MSc; Elliot A. Marseille, PhD; Jeffrey A. Tice, MD; Steve D. Pearson, MD, MSc; Daniel A. Ollendorf, PhD; Rena K. Fox, MD; James G. Kahn, MD, MPH

IMPORTANCE Novel treatments for hepatitis C virus (HCV) infection are highly efficacious but costly. Thus, many insurers cover therapy only in advanced fibrosis stages. The added health benefits and costs of early treatment are unknown.

OBJECTIVE To assess the cost-effectiveness of (1) treating all patients with HCV vs only those with advanced fibrosis and (2) treating each stage of fibrosis.

DESIGN, SETTING, AND PARTICIPANTS This study used a decision-analytic model for the treatment of HCV genotype 1. The model used a lifetime horizon and societal perspective and was representative of all US patients with HCV genotype 1 who had not received previous treatment. Comparisons in the model included antiviral treatment of all fibrosis stages (METAVIR [Meta-analysis of Histological Data in Viral Hepatitis] stages FO [no fibrosis] to F4 [cirrhosis]) vs treatment of stages F3 (numerous septa without cirrhosis) and F4 only and by specific fibrosis stage. Data were collected from March 1 to September 1, 2014, and analyzed from September 1, 2014, to June 30, 2015.

INTERVENTIONS Six HCV therapy options (particularly combined sofosbuvir and ledipasvir therapy) or no treatment.

MAIN OUTCOMES AND MEASURES Cost and health outcomes were measured using total medical costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs), calculated as the difference in costs between strategies divided by the difference in QALYs.

RESULTS We simulated 1000 individuals, but present the results normalized to a single HCV-infected person. In the base-case analysis, among patients receiving 8 or 12 weeks of sofosbuvir-ledipasvir treatment, treating all fibrosis stages compared with treating stages F3 and F4 adds 0.73 QALYs and \$28 899, for an ICER of \$39 475 per QALY gained. Treating at stage F2 (portal fibrosis with rare septa) costs \$19 833 per QALY gained vs waiting until stage F3; treating at stage F1 (portal fibrosis without septa), \$81 165 per QALY gained compared with waiting until stage F2; and treating at stage FO, \$187 065 per QALY gained compared with waiting until stage F1. Results for other regimens show a similar pattern. At base-case drug prices, treating 50% of all eligible US patients with HCV genotype 1 would cost \$53 billion. In sensitivity analyses, the ICER for treating all stages vs treating stages F3 and F4 was most sensitive to cohort age, drug costs, utility values in stages F1 and F2, and percentage of patients eligible for 8-week therapy. Except for patients aged 70 years, the ICER remains less than \$100 000 per QALY gained. A 46% reduction in cost of sofosbuvir-ledipasvir therapy decreases the ICER for treating at all fibrosis stages by 48%.

CONCLUSIONS AND RELEVANCE In this simulated model, treating HCV infection at early stages of fibrosis appeared to improve health outcomes and to be cost-effective but incurred substantial aggregate costs. The findings may have implications for health care coverage policies and clinical decision making.

JAMA Intern Med. doi:10.1001/jamainternmed.2015.6011
Published online November 23, 2015.

← Invited Commentary

+ Supplemental content at
jamainternalmedicine.com

Author Affiliations: Department of Clinical Pharmacy, University of California, San Francisco (Chahal); Global Health Economics Consortium, San Francisco, California (Chahal, Marseille, Kahn); Health Strategies International, Oakland, California (Marseille); Division of General Internal Medicine, Department of Medicine, University of California, San Francisco (Tice, Fox); Institute for Clinical and Economic Review, Boston, Massachusetts (Pearson, Ollendorf); Institute for Health Policy Studies, University of California, San Francisco (Kahn).

Corresponding Author: James G. Kahn, MD, MPH, Institute for Health Policy Studies, Global Health Economics Consortium, University of California, San Francisco, 3333 California St, Ste 265, PO Box 0936, San Francisco, CA 94118 (jgkahn@gmail.com).

In the United States, prevalence of chronic hepatitis C virus (HCV) infection is estimated to be 3.2 million and is the leading cause of liver-related deaths, hepatocellular carcinoma, and liver transplant.¹ The primary mode of acquisition is percutaneous exposure to blood, including sharing of injection paraphernalia and a historically contaminated blood supply, which led to a maximum prevalence in the cohort of individuals born from 1945 to 1965.^{2,3}

Previously, treatment of HCV genotype 1 required as long as 48 weeks, with cure rates of 40% to 70% in patients with HCV mono-infection.¹ With the introduction of HCV nucleotide analogue nonstructural protein 5A and B inhibitors, such as ledipasvir, ombitasvir, dasabuvir, and sofosbuvir, treatment duration has decreased for most patients to 12 weeks or less, with reduced toxic effects by the exclusion of interferon and often with the exclusion of ribavirin.⁴ The cure rate with the new therapies generally exceeds 90% and reaches 100% in some subgroups in clinical trials.⁴⁻⁷ The new drugs cost \$1000 per day or more based on the wholesale acquisition price.⁸ Such costs are prohibitive for many patients and health care systems. Health care professionals may therefore resort to less effective drugs or wait for disease progression before initiating treatment.

Recent cost-effectiveness studies show that treatment with new therapies compared with older drugs is cost-effective for patients with HCV genotype 1, with a net cost per quality-adjusted life-year (QALY) ranging from \$10 000 to \$30 000.^{9,10} These studies, however, do not analyze the implications of treatment at various stages of liver fibrosis. Thus, the optimal timing of treatment is unknown.

Despite clinical practice guidelines recommending the new antiviral drugs, some payers require a higher level of fibrosis before authorizing treatment.¹¹⁻¹⁵ Untreated chronic HCV infection can progress with increasing fibrosis, reaching cirrhosis in 20% to 30% of patients, and related liver complications, including premature death, in a smaller subset.¹⁶⁻¹⁸ Even with viral elimination, some patients may experience disease progression. Earlier treatment might provide important clinical and cost benefits. The objective of this study was to determine the most cost-effective liver fibrosis stage at which to initiate treatment with direct-acting antiviral agents in US treatment-naïve patients with HCV genotype 1 infection and was based on commonly accepted thresholds. We present an analysis of a fixed-dose combination of sofosbuvir and ledipasvir (hereinafter, sofosbuvir-ledipasvir). Other regimens are analyzed in eTable 1 in the [Supplement](#).

Methods

Model Overview

We constructed a decision-analytic model of HCV to examine the clinical outcomes and costs of treatment initiated at different disease stages. The disease states reflect progression through the 5 METAVIR (Meta-analysis of Histological Data in Viral Hepatitis) liver fibrosis stages (F0, no fibrosis; F1, portal fibrosis without septa; F2, portal fibrosis with rare septa; F3, numerous septa without cirrhosis; and F4, cirrhosis; eTable 1

in the [Supplement](#)) to advanced liver disease and regression of liver damage after successful treatment. We simulated a prevalent closed cohort (normalized to a single HCV-infected person) of US treatment-naïve patients with HCV genotype 1 until death, tracking costs and QALYs discounted to the present. We validated the model by comparing predictions with the results of empirical natural history studies and prior models. The cost-effectiveness of initiating treatment earlier was calculated by running the model twice, with different start times for antiviral therapy. Additional details are provided below and in the eMethods and eTable 2 in the [Supplement](#), and input variables are available in eTables 3 through 12 in the [Supplement](#). Data were collected from March 1 to September 1, 2014, and analyzed from September 1, 2014, to June 30, 2015. This project does not meet the criteria for human research and was not required to undergo evaluation by the University of California, San Francisco, Committee on Human Research.

Treatment Characteristics

The model considered therapies for HCV genotype 1 infection by regimens and doses approved by the US Food and Drug Administration.¹⁹ The goal of treatment is an undetectable serum level of HCV RNA 12 weeks after completion of therapy, also termed a *sustained virologic response* (SVR).²⁰ The likelihood of an SVR and treatment discontinuation were determined by meta-analyses of phases 2 and 3 clinical trials stratified by the presence or absence of cirrhosis.¹⁵ Discontinuation of therapy was calculated as patient withdrawal from clinical trials for any reason, with an intent-to-treat approach. The discontinuation and SVR rates were subjected to sensitivity analyses.

We present results for sofosbuvir-ledipasvir treatment for 8 or 12 weeks. Duration of sofosbuvir-ledipasvir treatment can be 8 weeks if the baseline viral load is less than 6 million IU/mL with no cirrhosis. Thus 67% of the patients with fibrosis stages F0 to F3 received 8 weeks of treatment and 33% received 12 weeks; all patients with stage F4 received 12 weeks of treatment.¹⁵ These proportions were varied in sensitivity analyses. We modeled 6 other HCV treatment regimens (eTable 1 in the [Supplement](#)).

Natural History of Chronic HCV

Chronic HCV progression through increasingly severe liver fibrosis is classified with fibrosis scores F0 to F4 (eTable 1 and eFigure 1 in the [Supplement](#)). We used these scores and major liver complications to define Markov model disease states (eFigures 1-3 in the [Supplement](#)). Transition probabilities between states are based on our review of the published literature. We validated this natural history model by demonstrating correspondence with empirical data on cirrhosis incidence and prior modeling (eTable 2 and eFigure 4 in the [Supplement](#)).^{21,22} The model starts with a prevalent cohort in which the patients are distributed across the 5 stages of fibrosis according to proportions observed in the US population with HCV infection.²³

Treatment Strategies

First, we compared treating all patients with treating patients who have disease progression to stage F3 or stage F4, the historical standard at which to consider treatment.¹¹⁻¹⁵ Second,

we compared treatment by fibrosis stage to assess finer distinctions. We considered 6 timing options. The first option treats all patients with HCV. The second option omits treatment of patients at stage F0 but includes those with stages F1 to F4. In this option, the patients with stage F0 disease must progress to stage F1 to be treated. Each successive option (third through fifth) adds 1 fibrosis stage. In the sixth option, for comparison, no treatment is provided.

Progression and Regression After SVR

Achieving SVR slows progression and liver complications by more than 90%.^{24,25} In addition, some patients experience regression of liver fibrosis after therapy.²⁵⁻³⁰ Our model portrays slowed progression via lowered transition probabilities and regression via new transition paths and values.

Patient Population

We simulated 1000 individuals, but present the results normalized to a single HCV-infected person. In our base-case scenario, we portray a cohort of 60-year-old patients (birth year, 1955) weighing 75 kg who are already aware of their HCV infection. The characteristics of patients in the analytic cohort were specified based on data from the 2010 National Health and Nutrition Examination Survey, indicating that 70% of HCV-infected persons were born from 1945 to 1965.³¹ As this cohort ages, the incidence of complicated liver conditions will increase.³²⁻³⁴ Other age cohorts ranging from 20 to 70 years are used for scenario analyses. The model does not distinguish patients on the basis of viral concentration, sex, or race, although these factors may affect treatment outcomes.³⁵

Mortality

Mortality for patients with stages F3 and F4 and no SVR is 2.37 times the age-specific background rates from the 2009 US life tables and based on evidence from a prospective cohort study.^{36,37} Individuals with decompensated cirrhosis and hepatocellular carcinoma have high rates of mortality.^{25,38} Patients who receive a liver transplant can die of transplant-related complications.^{25,38} Patients with stages F3 and F4 who achieve SVR have mortality 1.4 times the background population rate based on a meta-analysis of 8 HCV follow-up studies and input from HCV experts.³⁹ Mortality for patients with stages F0 to F2 was assumed to be equal to the rate for the background population.

Costs and Use of Health Care Resources

We adopted a societal perspective, including all direct medical costs for HCV management and therapy. Our intent is to portray societal costs, as approximated by the cost of care sources on which we rely. For unit costs based on reimbursement, the omission of small patient contributions slightly underestimates total costs (a synopsis of each study is provided in the eMethods in the Supplement). Owing to the imprecision of unit cost inputs and the greater uncertainty introduced by estimated rates of patients under current care and use of health care resources, we examined wide ranges of costs in our sensitivity analyses. Costs are in US dollars adjusted to 2014 using the medical component of the US Consumer Price Index.⁴⁰

Costs of drugs were determined using the wholesale acquisition price from Red Book Online⁸ in February 2015 and varied widely in sensitivity analyses. In a scenario analysis, drug costs were reduced by 46%, reflecting recent price reductions announced by Gilead Sciences, Inc.⁴¹

Annual health care costs associated with a diagnosis of chronic HCV were determined by adapting published empirical data to our cohort of individuals with known chronic HCV.⁴²⁻⁴⁴ Pre-SVR costs (\$810 for stages F0-F2, \$2150 for stage F3, and \$2575 for stage F4) were based on costs from a managed care database that were adjusted for the proportion of known chronic HCV cases estimated to receive health care.^{44,45} Post-SVR costs for stages F0 to F4 were estimated at 50% lower by taking the midpoint of 2 pre-SVR vs post-SVR cost ratios derived from medical care payment databases in the United States and the United Kingdom.^{42,46} The model accounted for costs of HCV genotyping, fibrosis staging, and therapy monitoring, including clinic visits, blood and hepatic tests, and HCV RNA quantification. These costs were determined using the Medicare reimbursement schedule and published literature.⁴⁷⁻⁴⁹ The frequency of monitoring visits and tests was based on HCV treatment guidelines and clinical judgment.^{11,50}

The costs of management of adverse effects were estimated using the frequency of common and serious adverse effects (determined using regimen-specific meta-analysis of clinical trials). We applied the published costs of similar adverse events.^{15,51}

Health State Utility Values

The model incorporates health state utility values by fibrosis stage with and without SVR and transient loss of utility during treatment. Utility values determined from a literature review indicate a utility score of 0.76 in stage F4, 0.79 in stage F3, 0.92 in stage F2, and 0.98 in stages F1 and F0. The SVR raises utility scores to 0.83 in stage F4, 0.86 in stage F3, 0.93 in stage F2, and 1.00 in stages F1 and F0. The utility penalty of treatment was modeled using utility weights of common and serious adverse events, weighted by the frequency of similar events observed in clinical trials.^{11,50}

Model Outcomes

The model produces discounted lifetime QALYs and direct medical costs for each strategy. It then calculates incremental cost-effectiveness ratios (ICERs) as the ratio of the difference in costs between treatment strategies divided by the difference in QALYs. A policy producing an ICER of \$150 000 per QALY or less was considered cost-effective; a policy producing an ICER of \$50 000 per QALY was considered highly cost-effective. The model was constructed using TreeAge Pro 2014,⁵² and Excel software⁵³ was used to analyze the data.

Sensitivity Analysis

We conducted 1-way sensitivity analysis on each variable to determine effects on the ICER and 2-way sensitivity analysis on selected variables. The aggregate uncertainty from multiple inputs was quantified via probabilistic sensitivity analysis using uniform distributions. The range in input values was determined by 95% CIs from primary literature sources or meta-

Table. Base-Case Results of HCV Treatment

Combined Sofosbuvir and Ledipasvir Treatment Strategy ^a	Base-Case Results				
	Costs, \$		QALYs		ICER, \$ per QALY Gained ^b
	Total Treatment	Incremental	Total	Incremental Gain	
Treat all vs treat at stages F3 and F4					
Treat at stage F3 or stage F4 ^c	60 906	NA	14.09	NA	NA
Treat all ^d	89 804	28 899	14.82	0.73	39 475
By fibrosis stage					
No treatment	46 107	NA	11.82	NA	NA
Treat at stage F4	57 616	11 509	12.85	1.02	11 252
Treat at stage F3	60 906	14 798	14.09	2.27	6522
Treat at stage F2	71 913	11 007	14.65	0.55	19 833
Treat at stage F1	83 594	11 682	14.79	0.14	81 165
Treat all	89 804	6210	14.82	0.03	187 065

Abbreviations: HCV, hepatitis C virus; ICER, incremental cost-effectiveness ratio; NA, not applicable; QALY, quality-adjusted life-year.


^a Sixty-seven percent of the patients with fibrosis stages F0 to F3 received 8 weeks of treatment and 33% received 12 weeks; all patients with stage F4 received 12 weeks.

^b Generated by comparing each policy with the one above (next least expensive).

^c Indicates wait and treat only when patients reach stages F3 and F4.

^d Indicates treat all patients as soon as they are identified with HCV in any fibrosis stage.

Figure 1. Cases of Advanced Liver Disease Averted by Treating All Stages of Fibrosis vs Stages F3 and F4



Percentages were calculated per 100 000 treated patients using 100 000 Monte Carlo simulations. For every 100 000 patients treated (treatment naive, prevalent cohort aged 60 years), the percentage of the advanced liver disease cases that could be averted by treating all stages with combined sofosbuvir and ledipasvir for 8 or 12 weeks compared with treating stages F3 and F4 only are

shown. By treating all stages of fibrosis vs waiting to treat at stages F3 and F4, the percentage of averted cases of liver transplant, decompensated cirrhosis, hepatocellular carcinoma, and liver death are 26%, 17%, 27%, and 25%, respectively. Fibrosis is measured using the METAVIR stages (described in the Model Overview subsection of the Methods section).

analyses. When such data were unavailable, we varied the base-case value from 50% to 150%.

Results

Base Case Results

We present results only for 8 and 12 weeks of sofosbuvir-ledipasvir treatment. Results for other regimens are similar and are presented in eTable 13 in the Supplement.

Treatment of All Stages vs Stages F3 and F4


For sofosbuvir-ledipasvir treatment for 8 and 12 weeks, treating all stages of fibrosis compared with treating stages F3 and F4 produced a QALY gain of 0.73 (Table) owing to a higher health state utility value after SVR in early fibrosis (69% of the QALY benefit) and to averted liver complications and death (Figure 1 and eTable 14 in the Supplement; 31% of the QALY benefit). Treating all stages of fibrosis compared with treating stages F3 and F4 increases drug costs by \$33 721. An SVR lowers lifetime health care costs by about \$5000, resulting in net increased costs of \$28 899 for sofosbuvir-ledipasvir treatment (Table and eTable 15 in the Supplement). Treating all

stages of fibrosis with sofosbuvir-ledipasvir compared with treating stages F3 and F4 only has net costs per QALY gained of \$39 475 (Table).

Treatment by Fibrosis Stage

Sofosbuvir-ledipasvir treatment at earlier stages of fibrosis results in a gain in QALYs (Table). Treating stage F3 increases QALYs by 2.27 compared with treating stage F4; treating stage F2 compared with stage F3 has a QALY gain of 0.55; treating stage F1 compared with stage F2 has a QALY gain of 0.14; and treating stage F0 compared with stage F1 has a QALY gain of 0.03. These QALY gains reflect higher health state utility values in early fibrosis and prevention of advanced liver complications, including premature death.

Treating stage F3 has a \$14 798 higher cost compared with waiting until stage F4 (Table). Incremental costs decrease with earlier fibrosis stage comparisons. The cost for treating stage F2 compared with stage F3 is \$11 007; for stage F1 compared with stage F2, \$11 682; and for stage F0 compared with stage F1, \$6210. The higher net costs for initiating treatment in earlier fibrosis stages are driven by the cost of drugs for individuals treated only under broader treatment criteria, which are partially offset by averted costs of care for chronic HCV and

Figure 2. Sensitivity Analyses of Incremental Cost-effectiveness Ratios (ICERs) for Combined Sofosbuvir and Ledipasvir Treatment for All Stages of Fibrosis vs Stages F3 and F4

The tornado diagram depicts 1-way sensitivity analyses for the inputs with the greatest effect on the ICER. Bars to the right of the base-case ICER (\$39 475 per quality-adjusted life-year [QALY] gained, represented by the vertical line) indicate an increase in the ICER relative to the base case to the upper limit of the input variable; bars to the left indicate the inverse. For example, as age increases from 20 years through the base-case age of 60 years to 70 years, the

ICER increases. A high-to-low order of the range, as for the annual cost of treating stage F0 disease and no sustained virologic response (SVR), indicates an inverse relationship between the input value and the ICER. Fibrosis is measured using the METAVIR stages (described in the Model Overview subsection of the Methods section). Drug therapy indicates sofosbuvir-ledipasvir.

advanced liver disease. As shown in the Table, the net cost per QALY gained by sofosbuvir-ledipasvir treatment is \$11 252 for treating stage F4 compared with no treatment, \$6522 for treating stage F3 compared with stage F4, \$19 833 for treating stage F2 compared with stage F3, \$81 165 for treating stage F1 compared with stage F2, and \$187 065 for treating stage F0 compared with stage F1.

Deterministic Sensitivity Analyses

The inputs to which the ICER for treating all fibrosis stages compared with treating stages F3 and F4 are most sensitive are cohort age and drug cost, with much lower sensitivity to discount rate, utility values in stages F1 and F2 (without SVR), and proportion of patients with disease regression to healthier fibrosis stages (Figure 2). For age, use of a cohort age of 50 years (vs 60 in the base-case analysis) produced the more favorable ICER or \$25 443 per QALY gained. At 20 years of age, the ICER is \$999 per QALY gained owing to a high likelihood of progression without SVR. At 70 years of age, the ICER is \$118 889 per QALY gained owing to the reduced likelihood of untreated chronic HCV causing death. For age analyses, age-dependent fibrosis progression probabilities were used with base-case fibrosis prevalence (eTable 4 in the Supplement). For drug prices, we referenced a recent announcement by Gilead Sciences, Inc (the manufacturer of sofosbuvir-ledipasvir), of a mean price discount to 46%.⁴¹ This reduction lowers the cost per QALY gained to \$18 807 for treating all stages vs treating

stages F3 and F4; similar trends are seen for analysis by fibrosis stage (eTable 16 in the Supplement). Sensitivity analyses on other regimens are available in eTables 17 to 19 and eFigures 5 to 8 in the Supplement.


Probabilistic Sensitivity Analysis

Monte Carlo simulations are shown in Figure 3 as the likelihood of a timing option to be considered cost-effective at different willingness-to-pay thresholds. At a willingness-to-pay threshold of \$50 000 per QALY, treating all stages is cost-effective in 74% of simulations. This proportion rises to 96% at a willingness-to-pay threshold of \$150 000 per QALY. Probabilistic sensitivity analyses for other regimens are available in eTable 13 and eFigures 9 to 12 in the Supplement.

Budget Impact Analysis

A prior analysis determined 1.32 million treatment-naive persons in the United States would be aware of their HCV infection status by 2014, with an additional 510 000 identified by 2019, for a total of 1.83 million patients.^{9,54} Assuming that 75% of these patients have HCV genotype 1 (1.37 million), we determined the total cost of drugs required to treat 25%, 50%, 75%, and 100% of these patients during the next 5 years in our budget impact analysis (full details are available in eTable 15 in the Supplement). Figure 4 shows the drug costs of sofosbuvir-ledipasvir treatment. If 50% of eligible patients with HCV genotype 1 (ie, 686 000 patients) are treated regardless of fi-

Figure 3. Cost-effectiveness Acceptability Curve for Combined Sofosbuvir and Ledipasvir Treatment for All Stages of Fibrosis vs Stages F3 and F4



Results of 10 000 Monte Carlo simulations (probabilistic sensitivity analysis) in which all input variables are varied simultaneously based on the listed ranges. The graph shows the percentage of simulations in which treating all patients (regardless of fibrosis stage) with sofosbuvir-ledipasvir for 8 or 12 weeks was considered cost-effective compared with treating only patients who reached fibrosis stages F3 and F4, depending on the willingness-to-pay (WTP) threshold. As the WTP increases (from left to right on the x-axis), the percentage of simulations resulting in treatment of all patients being cost-effective also increases. For example, for treatment at a WTP of \$50 000 per quality-adjusted life-year (QALY), treating all patients is cost-effective in 74%; at a WTP of \$150 000 per QALY, treating all patients is cost-effective in 96%. Fibrosis is measured using the METAVIR stages (described in the Model Overview subsection of the Methods section).


bro sis stage during the next 5 years, the estimated unadjusted treatment costs are \$53 billion. With the 46% reduction in drug prices discussed above, the cost decreases to \$29 billion. Alternatively, if 50% of these patients are treated at stages F3 and F4 during the next 5 years, the costs are \$30 billion with sofosbuvir-ledipasvir treatment and \$16 billion with a 46% decrease in drug prices. Figure 4 depicts the savings in lifetime health care costs exclusive of drug costs gained by treating all stages compared with treating stages F3 and F4, which is \$3.3 billion with sofosbuvir-ledipasvir treatment.

Discussion

The new HCV interferon-free therapies offer potentially huge individual and societal benefits but at a large cost. Health plans and health systems concerned about costs frequently require evidence of advanced liver fibrosis before authorizing the new therapies.¹¹⁻¹⁴ We herein examined the health impact, cost, and cost-effectiveness of earlier treatment.

Although early treatment with sofosbuvir-ledipasvir is expensive, the net cost is substantially lower owing to savings in medical care and the likelihood of later treatment with a delayed treatment policy. Furthermore, we found substantial short- and long-term health gains. Thus, for sofosbuvir-ledipasvir treatment, treating patients at all fibrosis stages compared with waiting for advanced fibrosis is cost-effective (<\$50 000 per QALY gained). A detailed analysis of timing of

Figure 4. Budget Impact Analyses for Initial Treatment of Patients



The figure shows total drug costs for treating 25%, 50%, 75%, and 100% of the 1.37 million treatment-naïve patients (identified during the next 5 years) with combined sofosbuvir and ledipasvir for 8 or 12 weeks. The analyses are subcategorized by treating all patients (treatment regardless of fibrosis stage) and treating only patients who reached stages F3 and F4. Offsets in savings in lifetime health care costs (exclusive of drug costs) achieved by treating all patients vs treating those with stages F3 and F4 are also shown. Fibrosis is measured using the METAVIR stages (described in the Model Overview subsection of the Methods section).

therapy by fibrosis stage shows that treating the disease as early as stage F1 is cost-effective (ICERs of \$50 000-\$150 000 per QALY gained) and less than \$50 000 per QALY gained when treatment is initiated at stage F2 vs stage F3. The ICER is lower when treatment is initiated at stage F3 compared with waiting for cirrhosis (stage F4). Results are similar for treatment with other new antiviral regimens.

Although the new therapies promise a high SVR, their long-term effects on clinical outcomes are not yet known. Sustained virologic response, a surrogate marker, may not lead to better long-term health outcomes with new treatments. Past studies with older regimens, however, have shown that achieving SVR can result in positive, long-term clinical benefits for patients.⁵⁵⁻⁶⁰ A 2011 systematic review⁶¹ found that achieving SVR can reduce liver-related mortality, incidence of hepatocellular carcinoma, and decompensation and foster regression of fibrosis and cirrhosis.

For budgetary considerations, if only 50% of eligible patients with HCV genotype 1 were to be treated with sofosbuvir-ledipasvir during the next 5 years, the cost of drugs in the United States would be \$53 billion at current prices. Many payers negotiate prices, as has been seen with exclusivity deals with drug manufacturers.⁶²⁻⁶⁵ If a mean 46% reduction in drug prices occurred, the cost of treating 50% of patients with HCV genotype 1 during the next 5 years could be as high as \$29 billion, partly offset by \$3 billion in savings in the management of chronic HCV and advanced liver disease.

Our model has several assumptions and limitations. First, we assumed that patients who achieve SVR have no risk for reinfection with HCV, thus tending to overestimate cost-effectiveness. Second, the model does not consider benefits for patients who receive therapy but do not achieve SVR. Third,

the model does not consider the reduction in HCV transmission to seronegative individuals as a consequence of successful therapy. These latter 2 assumptions would underestimate the societal and economic benefits of treatment.

Fourth, the model did not consider extended treatment for patients with slow responses or the repeated treatment of patients who do not achieve SVR. Additional therapy would add to the costs of treatment and possibly improve efficacy. Fifth, the model uses aggregated annualized transition probabilities to simulate progression from one clinical state to the next, adjusted for age but not for other individual traits. This approach focuses the overall simulation on population-level natural history. Individual heterogeneity in chronic hepatitis C virus progression is represented by varying progression rates in sensitivity analyses. Sixth, the analysis took into account only direct medical costs, omitting potential gains in productivity. Seventh, the model considered only patients monoinfected with HCV, excluding coinfections with hepatitis B virus and human immunodeficiency virus.

Eighth, we used meta-analyses of clinical trials to determine SVR and discontinuation rates. The point estimates may differ from those of published phases 2 and 3 trials. We used an intent-to-treat analysis to determine discontinuation rates, and our values may therefore be higher than other estimates. Point estimates from clinical trials may not represent real-world results, which can be lower for SVR and higher for discontinuation rates.^{66,67} However, our meta-analysis 95% CIs are wide, which allowed us to test SVRs across a wide range in sensitivity analyses.

Ninth, we had imperfect cost data. Costs for HCV care, treatment, and adverse effects are sparsely reported. We attempted to portray societal costs, as measured by the source studies. Our priority in selecting cost sources was addressing a scope of care closely aligned with our model categories. Owing to limited data, we never had to choose between multiple sources for the same data point; therefore, we had to rely on

the relevant source's costing methods (eMethods in the Supplement). However, the most challenging aspect of costing was extrapolating from very good costing data for the identified population receiving care (defined by ≥ 2 HCV codes in a year, thus likely omitting clinically healthy individuals with HCV) to the broader population receiving care and the even larger infected population. The future cost of new HCV therapy is also a major unknown. Because of these various uncertainties, we carefully explored the implications of different cost estimates for the cost-effectiveness outcomes via sensitivity analyses of the cost inputs and of the discount rate that affects the evaluation of future expected costs.

Finally, this model did not simulate changing drug costs over time and how that would affect the cost-effectiveness of early treatment. Market or political forces may result in significantly decreased drug costs in the next several years, and a subset of patients, given the slow progression of HCV, may be treated at a lower cost without a risk for serious clinical progression. These possibilities would make early treatment less cost-effective. However, as in the case of therapies for multiple sclerosis and insulin, the cost of drugs may increase despite being on the market for a number of years and despite new entrants.^{68,69}

Conclusions

This analysis suggests that treatment with new HCV drugs is cost-effective when started with any evidence of fibrosis (stage F1). Because of the investment required for these drugs, budgetary constraints on health systems typically restrict access to insured patients until they experience higher levels of liver damage or failure of older treatments, and uninsured patients would be unable to receive treatment without patient assistance programs. A reduction in the price will improve cost-effectiveness and increase affordability and access.

ARTICLE INFORMATION

Accepted for Publication: September 7, 2015.

Published Online: November 23, 2015.
doi:10.1001/jamainternmed.2015.6011.

Author Contributions: Drs Chahal and Marseille had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: All authors.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Chahal, Kahn.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Chahal, Kahn.

Obtained funding: Pearson, Kahn.

Administrative, technical, or material support: Chahal, Marseille, Tice, Ollendorf, Kahn.

Study supervision: Pearson, Ollendorf, Kahn.

Conflict of Interest Disclosures: None reported.

Funding/Support: This study was supported by the Blue Shield of California Foundation and the California Health Care Foundation (through the Institute for Clinical and Economic Review); by the

Clinical and Translational Sciences Institute, University of California, San Francisco; and by grant DA15612 from the National Institute on Drug Abuse, National Institutes of Health.

Role of the Funder/Sponsor: The Institute for Clinical and Economic Review collaborated on the design, conduct, and reporting of this study. The other funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: Karen Shore, PhD, Institute for Clinical and Economic Review, coordinated this effort. Jed Weissberg, MD, Institute for Clinical and Economic Review, and Marion Peters, MD, University of California, San Francisco, provided guidance on clinical issues. They received no compensation for these roles.

REFERENCES

1. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver

Diseases. Diagnosis, management, and treatment of hepatitis C: an update. *Hepatology*. 2009;49(4):1335-1374.

2. Papatheodoridis G, Hatzakis A. Public health issues of hepatitis C virus infection. *Best Pract Res Clin Gastroenterol*. 2012;26(4):371-380.

3. Taylor LE, Swan T, Mayer KH. HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. *Clin Infect Dis*. 2012;55(suppl 1):S33-S42.

4. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. *N Engl J Med*. 2013;368(20):1878-1887.

5. Hadziyannis SJ, Sette H Jr, Morgan TR, et al; PEGASYS International Study Group. Peginterferon- $\alpha 2a$ and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med*. 2004;140(5):346-355.

6. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. *N Engl J Med*. 2011;364(13):1195-1206.

7. Zeuzem S, Andreone P, Pol S, et al; REALIZE Study Team. Telaprevir for retreatment of HCV infection. *N Engl J Med*. 2011;364(25):2417-2428.
8. Truven Health Analytics. Micromedex 2.0 (Red Book Online). 2014. <http://www.micromedexsolutions.com/micromedex2/librarian/deeplinkaccess>. Accessed July 11, 2014.
9. Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. *Ann Intern Med*. 2015;162(6):397-406.
10. Najafzadeh M, Andersson K, Shrank WH, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. *Ann Intern Med*. 2015;162(6):407-419.
11. American Association for the Study of Liver Diseases; Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. <http://www.hcvguidelines.org>. Published 2015. Accessed July 16, 2014.
12. Anthem. Prior Authorization: Sovaldi (sofosbuvir). <https://www.anthem.com/pharmacyinformation/priorauth.html>. Accessed July 16, 2014.
13. HealthNet. Prior authorization protocol: Sovaldi (sofosbuvir). https://www.healthnet.com/static/general/unprotected/html/national/pa_guidelines/sovaldi_natl.html. Published December 9, 2013. Accessed July 16, 2014.
14. Tice JA, Ollendorf Daniel A, Pearson Steven D. The comparative clinical effectiveness and value of simeprevir and sofosbuvir in the treatment of chronic hepatitis C infection: a technology assessment. <http://ctaf.org/reports/treatments-hepatitis-c>. Published April 15, 2014. Accessed July 1, 2014.
15. Tice JA, Ollendorf DA, Chahal HS, et al. The comparative clinical effectiveness and value of novel combination therapies for the treatment of patients with genotype 1 chronic hepatitis C infection: a technology assessment. Institute for Clinical and Economic Review. <http://ctaf.org/reports/newest-treatments-hepatitis-c-genotype-1>. Published and accessed January 30, 2015.
16. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. *Int J Med Sci*. 2006;3(2):47-52.
17. Di Bisceglie AM. Natural history of hepatitis C: its impact on clinical management. *Hepatology*. 2000;31(4):1014-1018.
18. Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. *Best Pract Res Clin Gastroenterol*. 2012;26(4):401-412.
19. Gilead Sciences Inc. Sovaldi (sofosbuvir) prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204671s000lbl.pdf. Accessed April 1, 2014.
20. Chen J, Florian J, Carter W, et al. Earlier sustained virological response end points for regulatory approval and dose selection of hepatitis C therapies. *Gastroenterology*. 2013;144(7):1450-1455.e2.
21. Hagan LM, Sulkowski MS, Schinazi RF. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. *Hepatology*. 2014;60(1):37-45.
22. Thein H-H, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. *Hepatology*. 2008;48(2):418-431.
23. Bedossa P, Poynard T; METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. *Hepatology*. 1996;24(2):289-293.
24. Bruno S, Zuin M, Crosignani A, et al. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study. *Am J Gastroenterol*. 2009;104(5):1147-1158.
25. Hagan LM, Yang Z, Ehteshami M, Schinazi RF. All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses. *J Viral Hepat*. 2013;20(12):847-857.
26. D'Ambrosio R, Aghemo A, Rumi MG, et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. *Hepatology*. 2012;56(2):532-543.
27. Mallet V, Gilgenkrantz H, Serpaggi J, et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. *Ann Intern Med*. 2008;149(6):399-403.
28. Maylin S, Martinot-Peignoux M, Moucari R, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. *Gastroenterology*. 2008;135(3):821-829.
29. Pol S, Carnot F, Nalpas B, et al. Reversibility of hepatitis C virus-related cirrhosis. *Hum Pathol*. 2004;35(1):107-112.
30. Serpaggi J, Carnot F, Nalpas B, et al. Direct and indirect evidence for the reversibility of cirrhosis. *Human Pathol*. 2006;37(12):1519-1526.
31. Ditah I, Ditah F, Devaki P, et al. The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010. *J Hepatol*. 2014;60(4):691-698.
32. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. *Liver Transpl*. 2003;9(4):331-338.
33. McHutchison JG, Bacon BR. Chronic hepatitis C: an age wave of disease burden. *Am J Manag Care*. 2005;11(10)(suppl):S286-S295, S307-S311.
34. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. *Am J Public Health*. 2000;90(10):1562-1569.
35. Seeff LB. Natural history of chronic hepatitis C. *Hepatology*. 2002;36(5)(suppl 1):S35-S46.
36. Arias E. United States life tables, 2009. *Natl Vital Stat Rep*. 2014;62(7):1-63.
37. El-Kamary SS, Jhaveri R, Shardell MD. All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population. *Clin Infect Dis*. 2011;53(2):150-157.
38. Liu S, Cipriano LE, Holodny M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. *Ann Intern Med*. 2012;156(4):279-290.
39. Veldt BJ, Saracco G, Boyer N, et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. *Gut*. 2004;53(10):1504-1508.
40. US Department of Labor, Bureau of Labor Statistics. Consumer Price Index. <http://www.bls.gov/cpi/>. Published 2014. Accessed February 8, 2014.
41. *New lower prices for Gilead hepatitis C drugs reach CTAF threshold for high health system value* [press release]. San Francisco, CA: Institute for Clinical and Economic Review; February 17, 2015.
42. Backx M, Lewszuk A, White JR, et al. The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy. *J Viral Hepat*. 2014; 21(3):208-215.
43. Manos MM, Darbinian J, Rubin J, et al. The effect of hepatitis C treatment response on medical costs: a longitudinal analysis in an integrated care setting. *J Manag Care Pharm*. 2013;19(6):438-447.
44. Razavi H, Elkhoury AC, Elbasha E, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. *Hepatology*. 2013;57(6):2164-2170.
45. McAdam-Marx C, McGarry LJ, Hane CA, Biskupiak J, Deniz B, Brixner DI. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. *J Manag Care Pharm*. 2011;17(7):531-546.
46. Manos MM, Shvachko VA, Murphy RC, Arduino JM, Shire NJ. Distribution of hepatitis C virus genotypes in a diverse US integrated health care population. *J Med Virol*. 2012;84(11):1744-1750.
47. Centers for Medicare & Medicaid Services. Healthcare Common Procedure Coding System (HCPCS). <https://www.cms.gov/Medicare/Coding/MedHCPCSGenInfo/index.html?redirect=/medhcpcsgeninfo>. 2014. Accessed July 21, 2014.
48. Rein DB, Wittenborn JS. *The Cost-effectiveness of Birth Cohort and Universal Hepatitis C Antibody Screening in US Primary Care Settings: Technical Report*. Research Triangle Park, NC: RTI International; 2011.
49. Carlson JJ, Kowdley KV, Sullivan SD, Ramsey SD, Veenstra DL. An evaluation of the potential cost-effectiveness of non-invasive testing strategies in the diagnosis of significant liver fibrosis. *J Gastroenterol Hepatol*. 2009;24(5):786-791.
50. Department of Veterans Affairs. Chronic hepatitis C virus (HCV) infection: treatment considerations. Dept of Veterans Affairs National Hepatitis C Resource Center Program and Office of Public Health. <http://www.hepatitis.va.gov/provider/guidelines/2014hcv/lab-monitoring.asp>. March 27, 2014. Accessed April 1, 2014.
51. Gao X, Stephens JM, Carter JA, Haider S, Rustgi VK. Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C. *Expert Rev Pharmacoecon Outcomes Res*. 2012;12(3):335-343.
52. TreeAge Software. *TreeAge Pro 2013*. Williamstown, MA: TreeAge Software Inc; 2013.
53. Microsoft. *Microsoft Excel*. Redmond, WA: Microsoft; 2013.
54. Kabiri M, Jazwinski AB, Roberts MS, Schaefer AJ, Chhatwal J. The changing burden of hepatitis C virus infection in the United States: model-based predictions. *Ann Intern Med*. 2014;161(3):170-180.

55. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. *Clin Gastroenterol Hepatol*. 2011;9(6):509-516.e1.
56. Cardoso AC, Moucari R, Figueiredo-Mendes C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. *J Hepatol*. 2010;52(5):652-657.
57. McCombs J, Matsuda T, Tonnu-Mihara I, et al. The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs clinical registry. *JAMA Intern Med*. 2014;174(2):204-212.
58. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. *Ann Intern Med*. 2013;158(5, pt 1):329-337.
59. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. *JAMA*. 2012;308(24):2584-2593.
60. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. *Ann Intern Med*. 2007;147(10):677-684.
61. Ng V, Saab S. Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C. *Clin Gastroenterol Hepatol*. 2011;9(11):923-930.
62. Reuters. Anthem selects Gilead as primary supplier of hepatitis C drugs. <http://www.reuters.com/article/2015/01/08/anthem-gilead-hepatitis-idUSL1NOUN2IV20150108>. Published January 8, 2015. Accessed April 15, 2015.
63. Express scripts and AbbVie make hepatitis C cure available to millions of patients in need [press release]. St Louis, MO: Express Scripts; December 22, 2014.
64. Walker J. CVS gives preferred status to Gilead's hepatitis C drugs. *Wall Street Journal*. <http://www.wsj.com/articles/cvs-gives-preferred-status-to-gilead-hepatitis-c-drugs-1420478490>. Published January 5, 2015. Accessed April 15, 2015.
65. Congressional Budget Office. Prices for brand-name drugs under selected federal programs. <http://www.cbo.gov/sites/default/files/cbofiles/ftpdocs/64xx/doc6481/06-16-prescriptdrug.pdf>. Published June 2005. Accessed June 1, 2014.
66. Brennan TA, Lotvin A, Shrank W. Analysis of "real world" Sovaldi (sofosbuvir) use and discontinuation rates. CVS Health. https://www.cvshealth.com/sites/default/files/styles/SovaldiUseAndDiscontinuation_ResearchArticle_PDF.pdf. September 2014. Accessed October 1, 2014.
67. Belperio PS. Treating hepatitis C in Veterans Affairs (VA): early experience with sofosbuvir-based regimens. Palo Alto, CA: VA Office of Public Health/Population Health and VA Pharmacy Benefits Management Services, Dept of Veterans Affairs. <http://www.hepatitis.va.gov/pdf/white-paper-sofosbuvir-regimens.pdf>. Published October 31, 2014. Accessed November 1, 2014.
68. Hartung DM, Bourdette DN, Ahmed SM, Whitham RH. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail? *Neurology*. 2015;84(21):2185-2192.
69. Luo J, Avorn J, Kesselheim AS. Trends in Medicaid reimbursements for insulin from 1991 through 2014 [published online August 24, 2015]. *JAMA Intern Med*. doi:10.1001/jamainternmed.2015.4338.